XML 28 R16.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Stockholders' Equity
3 Months Ended
Mar. 31, 2024
Stockholders' Equity  
Stockholders' Equity

Note 9 – Stockholders’ Equity

At-The-Market Offering

During the three months ended March 31, 2024, the Company received approximately $3.2 million in net proceeds from the sale of 1,833,323 shares of its common stock pursuant to a sales agreement (the “Sales Agreement”) with Leerink Partners, LLC, formerly known as SVB Securities LLC (“Leerink Partners”) in an ”at-the-market” offering.

Stock-Based Compensation Expense

The Company records stock-based compensation expense related to stock options and restricted stock units (“RSUs”). For the three months ended March 31, 2024 and 2023, the Company recorded stock-based compensation expense of $546,232 ($206,586 which was included within research and development expenses and $339,646 was included within general and administrative expenses on the statements of operations) and $819,064 ($375,130 of which was included within research and development expenses and $443,934 was included within general and administrative expenses on the statements of operations), respectively.

Restricted Stock Units

A summary of the restricted stock units (“RSUs”) activity during the three months ended March 31, 2024 is presented below:

Weighted

Average

Number of

Exercise

    

RSUs

    

Price

RSUs non-vested January 1, 2024

 

106,019

$

2.12

Granted

 

 

Vested

 

 

Forfeited

 

 

RSUs non-vested March 31, 2024

 

106,019

$

2.12

Vested RSUs undelivered March 31, 2024

 

135,745

$

2.22

To date, RSUs have only been granted to directors in accordance with the Company’s Amended and Restated 2018 Omnibus Stock Incentive Plan. The Company’s policy is not to deliver shares underlying the RSUs until the termination of service.

As of March 31, 2024, there was $63,095 of unrecognized stock-based compensation expense related to RSUs which will be recognized over a weighted average period of 0.3 years.

Stock Options

A summary of the option activity during the three months ended March 31, 2024 is presented below:

    

    

    

    

    

Weighted

    

    

 

Weighted

 

Average

 

Average

 

Remaining

 

Aggregate

 

Number of

 

Exercise

 

Life

 

Intrinsic

 

Options

 

Price

 

In Years

 

Value

Outstanding, January 1, 2024

 

5,306,377

$

3.31

 

  

 

  

Granted

 

863,000

 

1.88

 

  

 

  

Exercised

 

 

 

  

 

  

Forfeited

 

(146,500)

1.27

 

Outstanding, March 31, 2024

6,022,877

$

3.19

6.9

$

Exercisable, March 31, 2024

 

4,147,529

$

3.63

 

5.8

$

The following table presents information related to stock options as of March 31, 2024:

Options Outstanding

 

Options Exercisable

 

Weighted

 

Outstanding

 

Average

 

Exercisable

Exercise

 

Number of

 

Remaining Life

 

Number of

Price

    

Options

    

In Years

    

Options

$1.00 - $1.99

 

2,299,482

4.5

 

1,049,492

$2.00 - $2.99

 

1,446,663

6.6

 

995,502

$3.00 - $3.99

 

898,528

6.3

 

781,568

$4.00 - $4.99

 

333,000

7.4

 

275,930

$5.00 - $5.99

 

50,805

3.5

 

50,638

$6.00 - $6.99

 

843,759

5.9

 

843,759

$7.00+

 

150,640

4.0

 

150,640

6,022,877

5.8

4,147,529

In applying the Black-Scholes option pricing model to stock options granted, the Company used the following approximate assumptions:

For the Three Months Ended

March 31, 

    

2024

    

2023

Expected term (years)

5.85 - 10.00

 

5.85 - 10.00

Risk free interest rate

4.04% - 4.24%

3.60% - 4.18%

Expected volatility

80% - 82%

82% - 83%

Expected dividends

0.00%

0.00%

As of March 31, 2024, there was $2,407,571 of unrecognized stock-based compensation expense related to stock options which will be recognized over a weighted average period of 2.1 years.

The weighted average estimated grant date fair value of the stock options granted for the three months ended March 31, 2024 and 2023 was approximately $1.33 and $1.61 per share, respectively.